Keyphrases
Statins
94%
Low-density Lipoprotein Cholesterol (LDL-C)
88%
Atherosclerotic Cardiovascular Disease (ASCVD)
57%
Coronary Artery Disease
50%
High-density Lipoprotein Cholesterol (HDL-C)
43%
Lipoproteins
41%
Cardiovascular Risk
39%
Statin Therapy
38%
Myocardial Infarction
28%
Cardiovascular Events
28%
Blood Viscosity
27%
Type 2 Diabetes Mellitus (T2DM)
27%
Cardiovascular Disease
26%
Placebo
25%
Lipid-lowering Therapy
25%
LDL Cholesterol
24%
Cardiovascular Disease Events
23%
Clinical Trials
23%
Evolocumab
22%
Metabolic Syndrome
22%
Dyslipidemia
22%
Ezetimibe
22%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
21%
Lipids
21%
Hypercholesterolemia
20%
Low-density Lipoprotein Cholesterol Level
20%
Confidence Interval
19%
Atorvastatin
19%
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
18%
Acute Coronary Syndrome
18%
COVID-19
18%
Triglycerides
18%
Statin Use
17%
Diabetes
16%
Homozygous Familial Hypercholesterolemia (HoFH)
16%
US Adults
15%
Low-density Lipoprotein
15%
Medicare Beneficiaries
14%
Hospitalization
14%
Hypertriglyceridemia
14%
SPLA2
14%
High-intensity Statin
14%
Cholesterol
13%
Statin Intolerance
13%
Fibrinogen
13%
Evinacumab
13%
Rosuvastatin
13%
Alirocumab
12%
PCSK9 Inhibitors
12%
High Risk
12%
Pharmacology, Toxicology and Pharmaceutical Science
Statin (Protein)
100%
Low Density Lipoprotein Cholesterol
85%
Lipoprotein
57%
Ischemic Heart Disease
52%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
52%
Cardiovascular Disease
44%
Triacylglycerol
40%
High Density Lipoprotein Cholesterol
37%
Coronary Artery Atherosclerosis
37%
Cardiovascular Risk
35%
Dyslipidemia
35%
Placebo
34%
Heart Infarction
28%
Proprotein Convertase 9
28%
Atherosclerosis
28%
Clinical Trial
28%
Non Insulin Dependent Diabetes Mellitus
26%
Evolocumab
22%
High Density Lipoprotein
22%
Metabolic Syndrome X
22%
Low Density Lipoprotein
21%
Ezetimibe
20%
Lipoprotein A
20%
Disease
18%
Hypercholesterolemia
18%
Inflammation
17%
Fibrinogen
16%
Hypertriglyceridemia
16%
Acute Coronary Syndrome
16%
Hyperlipidemia
15%
HIV
13%
Familial Hypercholesterolemia
13%
Evinacumab
13%
Adverse Event
13%
Rosuvastatin
12%
Atorvastatin
12%
Fenofibrate
11%
Biological Marker
11%
Symptom
11%
Randomized Clinical Trial
10%
Alirocumab
10%
Secretory Phospholipase A2
10%
1 Alkyl 2 Acetylglycerophosphocholine Esterase
9%
Varespladib Methyl
9%
Coronavirinae
9%
Combination Therapy
8%
Apolipoprotein B
8%
Thrombosis
8%
Coronary Artery Disease
8%
C Reactive Protein
7%
Medicine and Dentistry
Statin
37%
Low Density Lipoprotein Cholesterol
36%
Cardiovascular Disease
31%
Cardiovascular System
28%
Ischemic Heart Disease
25%
Dyslipidemia
18%
Cardiovascular Risk
17%
Diabetes
16%
Lipoprotein
15%
Apoplexy
15%
Myocardial Infarction
15%
Proprotein Convertase 9
14%
Atherosclerosis
14%
Clinical Trial
14%
High Density Lipoprotein Cholesterol
13%
COVID-19
13%
Maturity Onset Diabetes of the Young
13%
Coronary Artery Disease
12%
Triacylglycerol
12%
Drug Therapy
11%
Familial Hypercholesterolemia
10%
Disease
10%
Ezetimibe
8%
Metabolic Syndrome
8%
Chronic Kidney Disease
8%
High-Density Lipoprotein
8%
Patient with Diabetes
8%
Hypercholesterolemia
8%
Placebo
8%
Secondary Prevention
7%
Hypertriglyceridemia
7%
Evinacumab
7%
Thrombosis
7%
Brain Ischemia
6%
Acute Coronary Syndrome
6%
Human Immunodeficiency Virus
6%
Arteriosclerosis Obliterans
5%
C Reactive Protein
5%
Biological Marker
5%
Hyperlipidemia
5%
Risk Reduction
5%
Cohort Analysis
5%
Fenofibrate
5%
Randomized Clinical Trial
5%